Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock

About this update from Protagonist Therapeutics, Inc.

[{"type":"text","content":"NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,046,358 shares of its common stock at a price to the public of $37.75 per share. Gross proceeds to Protagonist from the offering are expected to be approximately $115 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Protagonist. In connection with this offering, Protagonist has granted the underwriters a 30-day option to purchase up to 456,953 additional shares of its common stock at the public offering price less underwriting discounts and commissions.\nJ.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler are acting as joint book-running managers for the offering. JMP Securities LLC and H.C. Wainwright & Co., LLC are acting as co-lead managers for the offering. The offering is expected to close on or about June 18, 2021, subject to satisfaction of customary closing conditions.\nA shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC) on December 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and a final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus. Copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at [email protected]; Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022; telephone: 877-821-7388; email: [email protected]); or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected].\nThis pr...

More updates from Protagonist Therapeutics, Inc.